Welcome to our dedicated page for Soleno Therapeutics SEC filings (Ticker: SLNO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Soleno Therapeutics filings document the regulatory, financial, governance, and capital-structure disclosures of a Nasdaq-listed biopharmaceutical company commercializing VYKAT XR for hyperphagia associated with Prader-Willi syndrome. Recent Form 8-K reports cover operating results and launch updates, regulatory and marketing-authorization matters for diazoxide choline, material agreements, share-repurchase arrangements, and the company's common stock registration on Nasdaq.
The filing record also includes board-approved bylaw amendments, officer appointments and compensation arrangements, exhibits to earnings releases, and material-event disclosures related to strategic transactions. These documents formalize the company's public reporting around product commercialization, corporate governance, executive compensation, and risk-related business developments.
Soleno Therapeutics, Inc. is sharing an investor presentation for use in previously scheduled meetings with existing and potential investors as part of a non-deal roadshow hosted by Guggenheim Securities and Piper Sandler on August 18–19, 2025. The slide deck is furnished as Exhibit 99.1 to this current report. The company states that this material, including Exhibit 99.1, is provided under Item 7.01 and is not deemed “filed” for purposes of Section 18 of the Exchange Act, nor automatically incorporated into other Securities Act or Exchange Act filings unless specifically referenced.
Form 144 filed for Soleno Therapeutics, Inc. (SLNO) reports a proposed sale of 1,347,522 shares of common stock, representing approximately 2.54% of the 53,145,009 shares outstanding. The filing shows an approximate sale date of 08/11/2025 through BTIG, LLC on NASDAQ with an aggregate market value of $110,696,581.49. The shares were acquired in two lots: 860,980 shares purchased from the issuer on 06/26/2020 for cash, and 486,542 shares acquired upon net exercise of warrants on 08/11/2025 with payment dated 03/31/2022 noted for the latter lot. The filer certifies no undisclosed material adverse information and declares no sales in the past three months.
Soleno Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,001,350 shares of Soleno common stock as of June 30, 2025. That holding represents 1.99% of the class. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that the positions were acquired and are held in the ordinary course of business, not to influence control.
Janus Henderson Group plc reports beneficial ownership of 5,308,009 shares of Soleno Therapeutics, Inc. (CUSIP 834203309), representing approximately 10.5% of the outstanding common stock as of the report. The filing shows shared voting and dispositive power over those shares and discloses a related holding by JHIUS of 5,241,409 shares (10.4%). The report lists the transaction date requiring the filing as 06/30/2025 and is signed on behalf of Janus Henderson on 08/14/2025.
The registrant certifies the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control. The filing includes a power-of-attorney dated December 9, 2022, authorizing named officers to execute ownership reports on the company's behalf.
Soleno Therapeutics reported that Avoro Capital Advisors LLC and Behzad Aghazadeh beneficially own 2,050,000 shares of common stock, equal to 4.1% of the outstanding class based on 50,393,931 shares. Avoro holds the position on behalf of Avoro Life Sciences Fund LLC and Dr. Aghazadeh serves as portfolio manager and controlling person of Avoro. The filing states the shares were acquired solely for investment purposes and that the reporting persons have sole voting and sole dispositive power over the reported shares. The statement indicates the position is below a 5% threshold and is not held to change or influence control of the issuer.
Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC report beneficial ownership of 3,958,294 shares of Soleno Therapeutics common stock, representing 7.4% of the class based on 53,145,009 shares outstanding as of August 1, 2025. The reporting persons state they have sole voting and sole dispositive power over those shares and that the shares are held of record by the fund.
The filing is a Schedule 13G amendment and includes a certification that the securities were not acquired to change or influence control of the issuer, indicating the reporting persons characterize the position as passive.
Adage Capital Management, L.P., together with reporting persons Robert Atchinson and Phillip Gross, disclose beneficial ownership of 3,575,964 shares of Soleno Therapeutics common stock, representing 7.10% of the outstanding shares (based on 50,393,931 shares outstanding as reported in the company filings). The holdings are shown as shared voting power and shared dispositive power; no sole voting or sole dispositive power is reported.
The filing is a Schedule 13G/A and includes a certification that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.